NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Phase 2
Completed
- Conditions
- Cholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderGastrointestinal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00356889
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Belinostat in Treating Patients With Myelodysplastic Syndromes
Phase 2
Completed
- Conditions
- Previously Treated Myelodysplastic SyndromesSecondary Myelodysplastic Syndromesde Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00357162
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: bevacizumabOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00357318
- Locations
- πΊπΈ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
πΊπΈCase Western Reserve University, Cleveland, Ohio, United States
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 2
Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Biological: VEGF Trap
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT00357760
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00357708
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00357305
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
πΊπΈUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
PXD101 in Treating Patients With Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Untreated Adult Acute Myeloid Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00357032
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
Study of Effects From Gastric Bypass Weight Loss on Brain Tissue
Completed
- Conditions
- Weight Loss
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 80
- Registration Number
- NCT00357344
- Locations
- πΊπΈ
NIDDK, Phoenix, Phoenix, Arizona, United States
πΊπΈGood Samaritan Regional Medical Center, Phoenix, Arizona, United States
πΊπΈMayo Clinic, Scottsdale, Arizona, United States
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase 1
Terminated
- Conditions
- Anaplastic Large Cell LymphomaRecurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Biological: monoclonal antibody SGN-30Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00354107
- Locations
- πΊπΈ
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 2
Completed
- Conditions
- Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00354250
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States